Plasma Thrombin Activatable Fibrinolysis Inhibitor and Tissue Factor Pathway Inhibitor Changes Following Sepsis

Abstract

Sepsis-induced systemic inflammation results in coagulation abnormalities that may be different in gram-positive and gram-negative infections. We used ciprofloxacin to induce a predominantly gram-positive Enterococcus faecalis polymicrobial sepsis in rats. Ciprofloxacin-untreated rats exhibited a predominantly gram-negative polymicrobial sepsis. Rats were subjected to 30% body surface area burn (B), cecal ligation puncture (CLP) with a 22-gauge needle, and B + CLP. Ciprofloxacin-treated B + CLP rats showed a significant decrease in plasma thrombin activatable fibrinolysis inhibitor (TAFI) levels compared with sham rats. However, plasma tissue factor pathway inhibitor (TFPI) levels decreased significantly in B, CLP, and B + CLP groups compared with sham rats. The ciprofloxacin-untreated group showed a significant decrease in plasma TAFI levels in CLP and B + CLP and plasma TFPI levels decreased in all 3 groups compared with sham rats. Histological changes in the liver and kidney included vascular congestion and parenchyma bleed following B + CLP in ciprofloxacin-untreated rats. These results suggest that plasma TAFI and TFPI levels differ depending on the type of bacteria involved in the septic process.

Keywords

TAFI TFPI CLP Burn Ciprofloxacin Polymicrobial sepsis.

References

Vallet B. Bench to bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care. 2003 ;7:130-138.

Opal SM , Esmon CT Bench to bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23-38.

Morris PE , Hite RD , Ohl C.

Relationship between the inflammation and coagulation pathways with severe sepsis: implications for therapy with activated protein C

Biodrugs. 2002;16:403-417.

Bouma BN , Mosnier LO Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb . 2003;33: 375-381.

Broze GJ Jr.The rediscovery and isolation of TFPI. J Thromb Haemost. 2003;1:1671-1675.

Nesheim M. , Wang W. , Boffa M. , Naqashima M. , Morser J. , Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997;78:386-391.

ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis . Crit Care Med. 2000;28(Suppl9): S9-S11.

Miragliotta G. Endotoxin release after antibiotic treatment and its potential pathogenetic role in coagulative disorders of patients with gram-negative sepsis. J Chemother. 1991;3(Suppl 1):69-72.

Taylor FB Jr.The inflammatory-coagulant axis in the host response to gram-negative sepsis: regulatory roles of proteins and inhibitors of tissue factor. New Horiz. 1994;2: 555-565.

10.

Rapaport SI The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost. 1991;66:6-15.

11.

Meijers JC , Oudijk EJ , Mosnier LO , et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute pro-myelocytic leukemia. Br J Haematol. 2000;108: 518-523.

12.

Asai S. , Sato T. , Tada T. , et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol. 2004;173: 4669-4674.

13.

Golino P. , Ragni M. , Cimmino G. , Forte L. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev. 2002 ; 20:67-80.

14.

Kinasewitz GT , Yan SB , Basson B. , et al; PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation in patients with severe sepsis regardless of causative microorganism. Crit Care. 2004;8(2): R82-R90.

15.

Gando S. , Kameue T. , Morimoto Y. , Matsuda N. , Hayakawa M. , Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002;30:1729-1734.

16.

Elsayed YA , Nakagawa K. , Kamikubo YI , et al. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am J Clin Pathol. 1996;106:574-583.

17.

Hack CE , Zeerleder S. The endothelium in sepsis: source of and a target for inflammation . Crit Care Med. 2001; 29(Suppl 7):S21-S27.